Replay available

IDEXX Laboratories, Inc. (IDXX) Q3 2025 Earnings Call

IDEXX Laboratories, Inc. (NASDAQ: IDXX) Q3 2025 earnings conference call, held 2025-11-03. Replay captured from the company's public earnings webcast.

Mon, November 3, 2025 at 8:30 AMendedReplay
IDEXX Laboratories, Inc. (IDXX) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

John Ravis

Vice President, Investor Relations

Andrew Emerson

Chief Financial Officer

Jay Mazelski

President and Chief Executive Officer

Erin Wright

Analyst, Morgan Stanley

Michael Riskin

Analyst, Bank of America

John Block

Analyst, Stifel

Chris Schott

Analyst, J.P. Morgan

Daniel Clark

Analyst, LearRink Partners

Brandon Vasquez

Analyst, William Blair

Andrea Alfonso

Analyst, UBS

Keith DeVos

Analyst, Jefferies

Replay transcript excerpt

Good morning, and welcome to the IDEXX Laboratory's third quarter 2025 earnings conference call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelski, President and Chief Executive Officer, Andrew Emerson, Chief Financial Officer, and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the investor relations section of our website, IDEX.com. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is provided in our earnings release, which may also be found by visiting the investor relations section of our website. In reviewing our third quarter 2025 results and updated 2025 guidance, please note all references to growth, organic growth, and comparable growth refer to growth compared to the equivalent prior year period unless otherwise noted. To allow broad participation in the Q&A, we ask that each participant limit their questions to one with one follow-up as necessary. We appreciate you may have additional questions, s...

More from Idexx Laboratories, Inc.